疟疾疫苗部署进展与现场挑战更新
本文为叙述性综述,检索近5年文献及WHO和GAVI报告,梳理RTS,S/AS01和R21/Matrix-M两种疟疾疫苗的已知信息、部署策略、现场挑战和实施研究。截至2026年2月,撒哈拉以南非洲已有25个国家将疫苗纳入常规免疫规划,但资金、产能、递送策略和疫苗犹豫等问题亟待解决。
要点
- WHO推荐的两种疟疾疫苗RTS,S和R21已在撒哈拉以南非洲25国常规免疫中引入。
- 现场部署面临资金限制、生产能力、递送策略和疫苗犹豫等挑战。
- 下一代疫苗可能提高保护效力和持久性,并减少传播以支持全球消除。
核心结论
- 两种疟疾疫苗大规模推广在撒哈拉以南非洲快速推进,但实施挑战需尽快解决以在目标人群获得显著影响。
- 下一代疫苗可能改善对临床疟疾的保护效力和持久性,并降低媒介传播活性以支持全球消除。
研究设计与样本
- 叙述性综述,基于近5年相关文献检索及WHO和GAVI等全球卫生组织的报告和政策文件。
主要发现
- 截至2026年2月,撒哈拉以南非洲已有25个国家将疟疾疫苗纳入常规免疫规划。
- 当前实施挑战包括资金约束、生产能力、递送策略和疫苗犹豫。
关键数值与推荐
- WHO全球疟疾技术战略2016-2030旨在2030年实现全球疟疾发病率下降90%。
临床怎么用
- 在撒哈拉以南非洲疟疾流行区,应推进RTS,S或R21纳入常规免疫规划并同步解决资金与递送障碍。
局限性
- 本文为叙述性综述,非系统评价,未报告原始研究的具体样本量或效应值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria is a life-threatening but preventable and treatable parasitic disease that remains a serious global health challenge. To meet the World Health Organisation (WHO) Global Technical Strategy for Malaria 2016-2030, which aims to achieve a 90% reduction of global malaria incidence by 2030, accelerated efforts are required. Interestingly, the advent of the first two licensed malaria vaccines, RTS,S/AS01 (RTS,S) and R21/Matrix-M (R21), has marked a new era in the global fight against malaria. OBJECTIVE: To provide an update on malaria vaccine deployment and challenges in the field. SOURCES: This narrative review is based on a relevant literature search spanning the last 5 years, as well as reports and policy documents from global health organisations, including WHO and GAVI (The Vaccine Alliance). CONTENT: The following topics are covered: (1) what is known about the first two WHO-recommended malaria vaccines (RTS,S and R21), (2) current delivery strategies used for malaria vaccine deployment in the field, (3) challenges in current malaria vaccine deployment, (4) current malaria vaccine implementation studies, and (5) upcoming perspectives in the field of malaria vaccine development. IMPLICATIONS: The roll-out of the first two malaria vaccines at large scale is progressing rapidly in sub-Saharan Africa, with 25 countries having introduced the vaccines in their routine immunisation programmes as of February 2026. However, current implementation challenges, including funding constraints, manufacturing capacity, delivery strategies, and vaccine hesitancy, should be quickly addressed to gain significant impact in targeted populations. Next-generation vaccines might improve the protective efficacy and durability against clinical malaria and reduce the transmission activity of the vectors to support global elimination efforts.
引用
- Natama HM, Rouamba T, Diallo S, et al. Update on malaria vaccine deployment and challenges in the field. Clin Microbiol Infect. 2026. PMID: 42648486. doi:10.1016/j.cmi.2026.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。